Macrosomia, top of the iceberg: The charm of underlying factors

Donma, Mustafa Metın

doi:10.1111/j.1442-200x.2010.03198.x

Cited by 19 publications

(23 citation statements)

References 32 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to metabolic consequences of antipsychotic medications, there are a number of other risk factors which may explain the increased incidence of diabetes in mentally ill patients including hereditary factors, poverty and poor access to good nutrition, physical inactivity, and antipsychotic medication use (reviewed in Holt et al, 2004 [42]). These changes in glucose homeostasis may explain, in part, the increased incidence of large for gestational age (LGA) babies born to women taking atypical antipsychotics during pregnancy as LGA is regarded as the most common fetal complication when women have GDM or preexisting diabetes [43–46]. …”

Section: Maternal Antipsychotic Use and Altered Birth Weight: Mechmentioning

confidence: 99%

Effect of Atypical Antipsychotics on Fetal Growth: Is the Placenta Involved?

Raha

Taylor

Holloway

2012

Journal of Pregnancy

View full text Add to dashboard Cite

There is currently considerable uncertainty regarding prescribing practices for pregnant women with severe and persistent psychiatric disorders. The physician and the mother have to balance the risks of untreated psychiatric illness against the potential fetal toxicity associated with pharmacological exposure. This is especially true for women taking atypical antipsychotics. Although these drugs have limited evidence for teratological risk, there are reports of altered fetal growth, both increased and decreased, with maternal atypical antipsychotic use. These effects may be mediated through changes in the maternal metabolism which in turn impacts placental function. However, the presence of receptors targeted by atypical antipsychotics in cell lineages present in the placenta suggests that these drugs can also have direct effects on placental function and development. The signaling pathways involved in linking the effects of atypical antipsychotics to placental dysfunction, ultimately resulting in altered fetal growth, remain elusive. This paper focuses on some possible pathways which may link atypical antipsychotics to placental dysfunction.

show abstract

Section: Maternal Antipsychotic Use and Altered Birth Weight: Mechmentioning

confidence: 99%

Effect of Atypical Antipsychotics on Fetal Growth: Is the Placenta Involved?

Raha

Taylor

Holloway

2012

Journal of Pregnancy

View full text Add to dashboard Cite

show abstract

“…Comorbidities associated with GDM include maternal hypertensive disorders, 6 increased risk of cesarean delivery and birth complications, as well as elevated risk of type 2 diabetes postpartum. 1 The established comorbidities are not isolated to the expectant mother: infants born to women with GDM are more likely to suffer from macrosomia, 7 hypoglycemia and hyperbilirubinemia, 8 as well as obesity and type 2 diabetes. 9 …”

Section: Introductionmentioning

confidence: 99%

Sleep duration and disorders in pregnancy: implications for glucose metabolism and pregnancy outcomes

O’Keeffe

St‐Onge

2012

Int J Obes

View full text Add to dashboard Cite

Humans have an innate requirement for sleep that is intrinsically governed by circadian and endocrine systems. More recently, reduced sleep duration has gained significant attention for its possible contribution to metabolic dysfunction. Significant evidence suggests that reduced sleep duration may elevate the risk for impaired glucose functioning, insulin resistance and type 2 diabetes. However, to date, few studies have determined the implications of reduced sleep duration with regard to glucose control during pregnancy. With the high prevalence of overweight and obesity in women of reproductive age, the occurrence of gestational diabetes mellitus (GDM) is increasing. GDM results in elevated risk of maternal and fetal complications, as well as increased risk of type 2 diabetes postpartum. Infants born to women with GDM also carry a life-long risk of obesity and type 2 diabetes. The impact of reduced sleep on glucose management during pregnancy has not yet been fully assessed and a paucity of literature currently exits. Herein, we review the association between reduced sleep and impaired carbohydrate metabolism and propose how reduced sleep during pregnancy may result in further dysfunction of the carbohydrate axis. A particular focus will be given to sleep-disordered breathing, as well as GDM-complicated pregnancies. Putative mechanisms of action by which reduced sleep may adversely affect maternal and infant outcomes are also discussed. Finally, we will outline important research questions that need to be addressed.

show abstract

“…En cuanto a diabetes gestacional (DG), la evidencia es muy escasa. Al respecto, un estudio realizado en Estambul analizó factores de riesgo de macrosomía en 6.385 recién nacidos, de los cuales 1.756 normopeso y 477 macrosómicos, tenían medición de grupo sanguíneo Abo 7 . Este estudio demostró que las madres de recién nacidos macrosómicos tenían mayor prevalencia de grupo A y las madres con grupo o tenían más frecuentemente DG, lo que sugiere que el grupo o tiene mayor riesgo de DG, y, dado que la macrosomía es más frecuente en DG podría indicar también un mayor riesgo de DG en el grupo A.…”

unclassified